TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21890335
Drug: Ciclesonide/Formoterol 320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide/Formoterol 320/9 μg bid (CIC/F)
Study: 21890335
Drug: Fluticasone Propionate/Salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Propionate/Salmeterol 250/50 μg bid (FP/S)
Study: 18541174
Drug: Highly discounted
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly discounted vaccine from local health departments
Study: 11086369
Drug: Androstenedione 100
Normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androstenedione 100 mg/d for 7 days
Study: 11086369
Drug: Androstenedione 300
Normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androstenedione 300 mg/d for 7 days
Study: 1552034
Drug: Buspirone (57
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (57 +/- 7 mg/day)
Study: 2863089
Drug: Bromazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (3 to 9 mg per day)
Study: 2863089
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 to 3 mg per day)
Study: 18653575
Drug: Other protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other protease inhibitors (Control)
Study: 16771937
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PPI and H. pylori testing
Study: 16771937
Drug: Empirical antisecretory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antisecretory therapy (PPI)
Study: 2166209
Drug: CY 216
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CY 216 (once daily)
Study: 30133164
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy for 12 weeks
Study: 4811950
Drug: Social therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social therapy for 12 weeks
Study: 28187400
Drug: Escitalopram plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram plus placebo (SSRI monotherapy)
Study: 28187400
Drug: Bupropion plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion plus escitalopram combination (bupropion-SSRI combination)
Study: 22527138
Drug: Alfacalcidol +
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol + 500 mg calcium (group A)
Study: 22527138
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D + 1000 mg calcium (group B)
Study: 19222323
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment over 17 weeks
Study: 14648310
Drug: Double-lumen totally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-lumen totally implantable subcutaneous port system (PORT)
Study: 11238504
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL isotonic saline i.v. at 0 min)
Study: 9669256
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (10 mg/min)
Study: 8310993
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg)
Study: 8310993
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (300 mg)
Study: 3047335
Drug: Vincristine, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine, cyclophosphamide, and doxorubicin (VCA) for six monthly cycles
Study: 29901736
Drug: LNS-LNS (Lipid-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNS-LNS (Lipid-Based Nutrient Supplements for women and children)
Study: 20925074
Drug: Orally dissolving
Normalized name: MUCOTROL Sugar-free Orally Dissolving Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally dissolving carbidopa/levodopa (OD C/L)
Study: 20925074
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral carbidopa/levodopa
Study: 11738543
Drug: Both sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sertraline and desipramine (responders)
Study: 11738543
Drug: Both sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sertraline and desipramine (non-responders)
Study: 11738543
Drug: Clinical change
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical change (not medication)
Study: 28089184
Drug: Bone wax
Normalized name: bone wax applicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone wax (2.5 g applied onto uncovered bone)
Study: 26177518
Drug: IdeS (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IdeS (intravenous single ascending doses)
Study: 26177518
Drug: IdeS (0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: IdeS (0.24 mg/kg)
Study: 23261172
Drug: Lisinopril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (40 mg/day) and a regular sodium diet (194 ± 49 mmol Na+/day)
Study: 23261172
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus valsartan (320 mg/day) and a low sodium diet (102 ± 52 mmol Na+/day)
Study: 23261172
Drug: Maximal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal treatment
Study: 17582922
Drug: Zonisamide plus
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide plus previous treatment
Study: 17582922
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus previous treatment
Study: 15044114
Drug: MTHFR genotypes
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTHFR genotypes (CC or CT)
Study: 11569889
Drug: Dolasetron 100
Normalized name: dolasetron 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 100 mg daily
Study: 11569889
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ondansetron or granisetron)
Study: 9814477
Drug: SB (steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB (steroid and LH free) after R‐FSH administration
Study: 934535
Drug: Reserpine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine (1.5 mg/1.7 m2 surface) administered as a single i.m. injection
Study: 934535
Drug: Prolonged reserpine
Normalized name: Reserpine
DrugBank: Reserpine (DB00206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged reserpine medication (0.2 mg reserpine 3 times a week for 6 weeks)
Study: 934535
Drug: Prolonged reserpine
Normalized name: Reserpine
DrugBank: Reserpine (DB00206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged reserpine medication
Study: 28525788
Drug: Intervention for
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention for stimulant abuse/dependence
Study: 17294169
Drug: 3-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day course of antibiotics and catheter replacement 4 hours after first antibiotic administration
Study: 17294169
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (no antibiotics, no catheter replacement)
Study: 17294169
Drug: 3-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day course of antibiotics and catheter replacement
Study: 15153170
Drug: Orlistat (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (3 x 120 mg/day)
Study: 2048868
Drug: Ciprofloxacin, 500
Normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg orally every 12 hours
Study: 31094774
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amisulpride
Study: 30488222
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amisulpride
Study: 23152584
Drug: Immunohistochemical assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical assay of sarcolemmal chloride channel abundance using 2 different ClC1‐specific antibodies
Study: 20551460
Drug: Azathioprine 2.0-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 2.0-2.5 mg/kg/day
Study: 16371154
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg single dose in second trimester)
Study: 12460041
Drug: Progressive resisted
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resisted isotonic quadriceps and hamstrings exercise and training on a cycle ergometer three times weekly for 12 weeks
Study: 10597763
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of phytonadione IV
Study: 10597763
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of phytonadione SC
Study: 1423955
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (20 mg followed by 25 mg bolus doses and 10 and 15 mg/hr infusion for 24 hours)
Study: 31444189
Drug: Lifestyle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle treatment (information emphasising the disease's lifestyle causes)
Study: 24499772
Drug: Moderate Fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Fat with 10 g of ground flaxseed added daily (n=49)
Study: 24499772
Drug: Moderate Fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Fat without 10 g of ground flaxseed added daily (n=49)
Study: 20854868
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) applied over the dorsolateral prefrontal cortex using a 2 mA-current for 20 min, twice-daily, for 5 consecutive days.
Study: 20155617
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carotenoids and myo‐inositol
Study: 17524594
Drug: High marking
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High marking of the argumentative orientation and daily estimates
Study: 15212190
Drug: Tulobuterol TTS
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol TTS (Hokunalin Tape) with inhalational steroids
Study: 15212190
Drug: Tulobuterol TTS
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol TTS (Hokunalin Tape) without inhalational steroids
Study: 15212190
Drug: Inhalational steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalational steroids
Study: 11769150
Drug: FPD patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPD patch
Study: 2427411
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received the infusion solution and vasodilator drugs
Study: 30766594
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg oral clonidine pre‐medication
Study: 30766594
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg oral clonidine pre‐medication
Study: 30766594
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral clonidine pre‐medication)
Study: 23756400
Drug: Shiitake mushroom
Normalized name: Shiitake Mushroom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shiitake mushroom extract (700 mg, two times per day)
Study: 20653494
Drug: Olanzapine orodispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine orodispersible tablet (ODT)
Study: 20653494
Drug: Oral conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral conventional tablet (OCT)
Study: 18408938
Drug: Pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 1 mg/kg (Group I, n = 60)
Study: 18408938
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg/kg (Group II, n = 50)
Study: 14555299
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 2 mg four times daily
Study: 19549432
Drug: CIC treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC treatments (all groups)
Study: 16401531
Drug: Training and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training and Support Programme (TSP) - 8 weekly sessions, 1 hour each, teaching massage skills
Study: 15253580
Drug: Control (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Conventional treatment)
Study: 8104272
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled salbutamol (200 micrograms four times daily for 2 weeks)
Study: 3769482
Drug: DHPA 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHPA 150 mg + E2‐EN 10 mg (group I, n = 9)
Study: 3769482
Drug: Half-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose of DHPA + E2‐EN (group II, n = 7)
Study: 27297013
Drug: Routine iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine iron prophylaxis (60 mg ferrous sulfate plus 400 μg folic acid daily)
Study: 27297013
Drug: Selective iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective iron prophylaxis (1 mg folic acid daily and Hb screening with treatment for low Hb)
Study: 24980710
Drug: Extended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended therapy (72 weeks of PEG‐IFNα‐2a)
Study: 24980710
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (48 weeks of PEG‐IFNα‐2a)
Study: 15948808
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg, all b.d., for the remaining 5 days)
Study: 15948808
Drug: Standard 7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 7-day triple regimen (rabeprazole 20 mg, clarithromycin 500 mg and amoxicillin 1 g, all b.d.)
Study: 6615689
Drug: Meptazinol 400
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 400 mg
Study: 6615689
Drug: Pentazocine 100
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocine 100 mg
Study: 26681132
Drug: Cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanol (CF) ingestion (900 mg CF per study day)
Study: 24716412
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + rhBNP (recombinant human B-type natriuretic peptide) for up to 7 days
Study: 19237881
Drug: Hemofiltration (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemofiltration (25 mL/kg/hr) for a 96-hour period
Study: 15689054
Drug: Novel polyherbal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel polyherbal formulation (PF; Aller‐7/NR‐A2)
Study: 11705489
Drug: Imatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib at a dose of 500 mg twice daily
Study: 11705489
Drug: Imatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib at a dose of 400 mg twice daily
Study: 7993413
Drug: Intravenous dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dobutamine (5 to 200 micrograms per kilogram of body weight per minute)
Study: 7993413
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dobutamine administered only if cardiac index was below 2.8 liters per minute per square meter)
Study: 3281701
Drug: Clonidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.6 mg by mouth 2 h before operation
Study: 29453232
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) 1,000 mg by mouth twice daily for 12 weeks
Study: 23833564
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg IV every 3 weeks for up to 4 doses)
Study: 23833564
Drug: Dacarbazine (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (850 mg/m2 IV every 3 weeks)
Study: 23833564
Drug: Carboplatin/paclitaxel (Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/paclitaxel (Paclitaxel 175 mg/m2 IV and Carboplatin [AUC=6] IV every 3 weeks)
Study: 23833564
Drug: Ipilimumab maintenance
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab maintenance (10 mg/kg every 12 weeks)
Study: 11583471
Drug: ketoconazole (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole (three 200 mg doses spaced 12 hours apart)
Study: 1099860
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam intravenously as preoperative sedative
Study: 15175486
Drug: Verbal descriptors
Normalized name: delavirdine mesylate Oral Tablet [Rescriptor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal descriptors (e.g., 'common' for constipation, 'rare' for pancreatitis)
Study: 15175486
Drug: Numerical descriptors
Normalized name: delavirdine mesylate Oral Tablet [Rescriptor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Numerical descriptors (e.g., 2.5% for constipation, 0.04% for pancreatitis)
Study: 11672493
Drug: Dexamphetamine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (up to 60 mg daily)
Study: 11672493
Drug: Counselling (weekly)
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Counselling (weekly)
Study: 30318837
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g·kg‐1 body mass)
Study: 30318837
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 0.2 g·kg‐1 body mass)
Study: 18303254
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (75 mg/day plus 75-162 mg/day)
Study: 16291412
Drug: Topical ketotifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketotifen fumarate 0.025% ophthalmic solution
Study: 16291412
Drug: Topical olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical olopatadine HCl 0.1% ophthalmic solution
Study: 12145231
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg (acute effect)
Study: 12145231
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg (prolonged effect after 2 weeks)
Study: 7614527
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg twice daily, up to 50 mg if needed) plus hydrochlorothiazide (HCTZ)
Study: 7614527
Drug: Digoxin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.1 mg twice daily) plus hydrochlorothiazide (HCTZ)
Study: 2393281
Drug: Cefprozil 250
Normalized name: cefprozil 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil 250 mg
Study: 2393281
Drug: Cefprozil 1000
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil 1000 mg
Study: 2393281
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg
Study: 57340
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of steroid drugs plus 600 rads of radiotherapy to the graft
Study: 26220326
Drug: Individually-defined therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually-defined therapy program (IT)
Study: 26220326
Drug: General therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General therapy program (GT)
Study: 19492250
Drug: NT-proBNP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP level in TOF patients repaired with transannular patch
Study: 19492250
Drug: NT-proBNP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP level in TOF patients operated on without transannular patch
Study: 11108723
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil diet (50 g of oil per 10 MJ)
Study: 11108723
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil diet (50 g of oil per 10 MJ)
Study: 11108723
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil diet (50 g of oil per 10 MJ)
Study: 6240210
Drug: atracurium (ATR)
DrugBank: Atracurium (DB13295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atracurium (ATR) 0.33 mg X kg‐1
Study: 6240210
Drug: alcuronium (DAN)
Normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcuronium (DAN) 0.1 mg X kg‐1
Study: 6240210
Drug: succinylcholine (SCH)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine (SCH) 1.0 mg X kg‐1
Study: 30044792
Drug: Anfoleish cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anfoleish cream administered 2 times per day (BID group) for 4 weeks
Study: 30044792
Drug: Anfoleish cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anfoleish cream administered 3 times per day (TID group) for 4 weeks
Study: 25546691
Drug: In-plane ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-plane ultrasound-guided injection with 40 mg of triamcinolone and 1 mL of 1% lidocaine
Study: 25546691
Drug: Out-plane ultrasound-guided
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-plane ultrasound-guided injection
Study: 25546691
Drug: In-plane ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-plane ultrasound-guided injection
Study: 17414691
Drug: Open-label, flexible-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label, flexible-dose antidepressant treatment for 8 weeks